NeoGenomics, Inc. NEO R2K

Healthcare · Diagnostics & Research · United States

https://www.neogenomics.com

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Market & Price

Market Cap

$1.37B

Current Price

$10.52

High / Low (52W)

$13.22 / $4.84

Beta

1.80

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

28.86

PEG Ratio

2.09

Book Value

$6.49

Price to Book

1.62

P/S

1.84

EV/EBITDA

382.52

Dividend Yield

Profitability & Returns

ROCE

-8.38%

ROE

-11.56%

ROA

-2.64%

Profit Margin

-13.30%

Op Margin

-9.34%

EPS (Latest Qtr)

$-0.13

EPS (TTM)

$-0.77

Balance Sheet & Liquidity

Debt/Equity

0.49

Quick Ratio

3.71

Current Ratio

4.42

Debt

$408.53M

Total Assets

$1.36B

Current Assets

$376.29M

Working Capital

$287.99M

Ownership

Promoter Holding

1.93%

Chg in Prom Hold

FII / Inst Holding

108.40%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$1.63B

Total Revenue (TTM)

$745.97M

EBITDA

$4.27M

Free Cash Flow

$33.17M

Operating Cash Flow

$22.42M

Shares Outstanding

130.21M

Gross Margin

43.10%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

12.58%

Profit 5Y

8.37%

Revenue (YoY)

11.10%

Earnings (YoY)

PROS

Compounding revenue at 12.6% over 5 years.
Generates positive free cash flow.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	NEO NeoGenomics, Inc. R2K	10.52	-	$1.37B	-	-8.38%	-11.56%	12.58%	8.37%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	57.43M	62.26M	-	-	63.42M	67.75M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	168.03M	181.33M	187.80M	190.17M	186.67M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	94.79M	104.07M	107.35M	106.83M	105.81M
Gross Profit	10.81M	11.17M	12.23M	27.17M	28.61M	27.34M	27.26M	22.95M	27.35M	24.89M	26.76M	27.30M	30.53M	32.32M	37.11M	47.12M	48.97M	50.83M	49.92M	46.37M	28.01M	54.06M	41.57M	52.99M	47.24M	38.23M	43.95M	48.89M	54.81M	59.89M	62.31M	65.47M	72.49M	74.88M	-	73.25M	77.26M	80.45M	83.34M	80.86M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	101.07M	104.84M	100.37M	96.13M	99.11M
Operating Income	28.00K	114.00K	-	1.92M	2.19M	1.40M	-	-580.00K	1.84M	-2.06M	-	2.50M	794.00K	3.92M	-	2.55M	4.48M	3.66M	-	-5.29M	-18.91M	4.67M	-15.11M	-22.37M	-39.71M	-52.03M	-39.70M	-39.51M	-35.07M	-29.89M	-24.20M	-30.57M	-21.94M	-21.20M	-	-27.82M	-27.59M	-19.93M	-12.79M	-18.24M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6.31M	-27.62M	-9.35M	4.59M	-567.00K
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.62M	933.00K	603.00K	599.00K	598.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-25.66M	-45.82M	-26.39M	-12.41M	-17.58M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	266.00K	-724.00K	740.00K	-2.52M	-472.00K
Net Income	-176.00K	-125.00K	-1.47M	155.00K	413.00K	-67.00K	-6.22M	-1.17M	483.00K	-4.26M	4.55M	644.00K	-380.00K	2.02M	353.00K	-2.42M	1.99M	2.14M	6.30M	-6.98M	-6.82M	2.56M	-22.11M	75.87M	-20.35M	-49.41M	-35.30M	-36.85M	-30.80M	-24.33M	-18.52M	-27.06M	-18.64M	-17.70M	-	-25.92M	-45.09M	-27.13M	-9.88M	-17.11M
Diluted EPS	0.00	0.00	-0.03	-0.07	-0.07	-0.07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.20	-0.35	-0.21	-0.08	-0.13
R&D Expense	803.00K	871.00K	-	1.45M	1.31M	967.00K	-	862.00K	947.00K	1.27M	-	956.00K	1.07M	446.00K	-	1.21M	2.59M	2.61M	-	2.06M	2.10M	1.96M	2.46M	3.50M	7.41M	7.71M	8.63M	7.31M	7.39M	7.50M	5.29M	7.62M	7.89M	7.68M	-	10.18M	9.02M	8.69M	-	9.53M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	231.81M	240.25M	276.74M	408.83M	444.45M	-	509.73M	591.64M	660.57M	727.33M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	321.83M	347.04M	370.47M	413.04M
Gross Profit	15.78M	19.43M	26.84M	31.74M	40.71M	43.76M	98.10M	101.96M	127.27M	196.84M	185.89M	-	187.90M	244.60M	290.10M	314.29M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	341.00M	341.25M	375.55M	402.42M
Operating Income	-2.96M	-409.00K	1.21M	3.17M	2.22M	-5.63M	2.15M	2.90M	10.04M	13.01M	-13.99M	-	-153.11M	-96.65M	-85.45M	-88.13M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-82.33M	-17.61M	-1.51M	-38.69M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	7.58M	6.91M	6.62M	3.75M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-159.34M	-97.10M	-80.67M	-110.27M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-15.09M	-9.13M	-1.95M	-2.24M
Net Income	-3.30M	-1.18M	65.00K	2.03M	1.13M	-2.54M	-6.14M	-396.00K	2.64M	8.01M	4.17M	-	-144.25M	-87.97M	-78.73M	-108.03M
Diluted EPS	-	-0.03	0.00	0.04	0.02	-0.04	-	-	-	-	-	-	-1.16	-0.70	-0.62	-0.84
R&D Expense	-	543.00K	2.28M	2.44M	2.69M	4.20M	4.65M	3.64M	3.00M	8.49M	8.23M	21.87M	30.33M	27.31M	31.16M	37.08M

Compounded Sales Growth

5 Years:	12.58%
1 Year:	11.10%

Compounded Profit Growth

5 Years:	8.37%
1 Year:	-

Stock Price Performance

1 Year:	+44.51%
6 Months:	-14.75%
3 Months:	+7.02%
1 Month:	+17.41%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	13.65M	19.95M	30.07M	39.92M	81.11M	351.29M	337.12M	344.45M	505.01M	709.51M	988.33M	-	1.74B	1.68B	1.64B	1.36B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	605.29M	596.81M	596.02M	376.29M
Cash & Equivalents	1.63M	1.10M	2.63M	1.87M	4.83M	33.69M	23.42M	12.53M	12.82M	9.81M	173.02M	228.71M	-	263.18M	342.49M	367.01M	159.62M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	24.28M	24.16M	26.75M	28.57M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	119.71M	131.23M	150.54M	159.24M
Total Liabilities	-	10.52M	14.05M	20.86M	18.20M	20.70M	113.17M	150.52M	139.88M	184.57M	202.10M	294.04M	-	742.01M	739.69M	735.70M	523.27M
Current Liabilities	-	9.17M	11.44M	17.76M	14.32M	14.62M	40.06M	38.11M	36.47M	60.92M	63.90M	73.18M	-	89.93M	96.30M	301.24M	88.30M
Long Term Debt	-	-	-	-	-	-	52.25M	91.95M	91.13M	92.88M	-	-	-	535.32M	538.20M	340.33M	341.86M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	610.93M	611.68M	605.33M	409.46M
Total Equity	5.64M	3.13M	5.90M	9.22M	21.71M	60.41M	208.52M	162.32M	171.96M	320.44M	507.41M	694.29M	-	998.02M	941.54M	902.34M	836.56M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	126.91M	127.37M	128.15M	128.99M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-2.05M	69.00K	-492.00K	2.23M	-	-	-	18.04M	44.79M	23.37M	1.46M	-	-65.99M	-1.95M	7.02M	5.23M
Investing Cash Flow	-916.00K	-897.00K	-3.65M	-2.01M	-	-	-	-13.69M	-139.69M	-19.63M	-159.44M	-	517.00K	76.71M	12.86M	-12.34M
Financing Cash Flow	2.43M	2.36M	3.38M	2.75M	-	-	-	-4.09M	91.96M	159.47M	235.60M	-	11.83M	4.55M	4.65M	-200.29M
Capital Expenditure	-916.00K	-897.00K	-2.62M	-2.01M	-3.77M	-2.21M	-7.54M	-13.69M	-14.31M	-20.03M	-29.10M	-	-30.89M	-28.75M	-41.06M	-27.01M
Free Cash Flow	-2.97M	-828.00K	-3.11M	216.00K	-	-	-	4.35M	30.48M	3.34M	-27.64M	-	-96.88M	-30.70M	-34.04M	-21.78M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-53.65M	79.31M	24.52M	-207.39M

Ratios (Annual)

Figures in %.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	42.3%	42.4%	46.0%	48.1%	41.8%	-	36.9%	41.3%	43.9%	43.2%
Operating Margin %	-	-	-	-	-	-	0.9%	1.2%	3.6%	3.2%	-3.1%	-	-30.0%	-16.3%	-12.9%	-12.1%
Net Margin %	-	-	-	-	-	-	-2.6%	-0.2%	1.0%	2.0%	0.9%	-	-28.3%	-14.9%	-11.9%	-14.9%
ROE %	-105.4%	-20.0%	0.7%	9.4%	1.9%	-1.2%	-3.8%	-0.2%	0.8%	1.6%	0.6%	-	-14.5%	-9.3%	-8.7%	-12.9%
ROCE %	-66.1%	-4.8%	9.8%	12.4%	3.3%	-1.8%	0.7%	0.9%	2.3%	2.0%	-1.5%	-	-9.3%	-6.1%	-6.4%	-6.9%

Shareholding Pattern

Insiders

1.93%

Institutions

108.40%

Public Float

110.54%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	15.33%	19.96M	$209.95M
2	First Light Asset Management, LLC	7.47%	9.73M	$102.36M
3	Greenhouse Funds, LLLP	6.99%	9.10M	$95.73M
4	Vanguard Portfolio Management LLC	5.85%	7.62M	$80.19M
5	First Trust Advisors LP	4.73%	6.16M	$64.83M
6	Vanguard Capital Management LLC	4.34%	5.66M	$59.50M
7	Braidwell LP	4.31%	5.62M	$59.10M
8	State Street Corporation	3.93%	5.12M	$53.86M
9	Shaw D.E. & Co., Inc.	3.20%	4.16M	$43.81M
10	Schroder Investment Management Group	2.74%	3.57M	$37.54M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NEO

No recent headlines available.

NEO · Healthcare

NeoGenomics, Inc.

About

Key Facts

Sector	Healthcare
Industry	Diagnostics & Research
Headquarters	United States
Employees	2,500
Website	https://www.neogenomics.com

Press Esc or click outside to close.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

NeoGenomics, Inc. NEO R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More